Does a high arachidonic acid:EPA ratio from omega-3 deficiency increase vascular reactivity and inflammation?

The balance between arachidonic acid (AA) and eicosapentaenoic acid (EPA) is a critical determinant of cardiovascular and systemic health. In states of omega-3 deficiency, a high AA:EPA ratio fundamentally alters cellular signaling, promoting a pro-inflammatory and pro-thrombotic environment.

Mechanistic basis of signaling shifts

AA and EPA compete for the same metabolic enzymes, primarily cyclooxygenase (COX) and lipoxygenase (LOX). When EPA levels are low, these enzymes preferentially metabolize AA, leading to a dominance of 2-series prostaglandins (e.g., PGE2) and 4-series leukotrienes (e.g., LTB4). These mediators are potent drivers of leukocyte chemotaxis and systemic inflammation. Conversely, higher EPA availability shifts production toward 3-series prostaglandins and 5-series leukotrienes, which exhibit significantly lower inflammatory activity. Furthermore, EPA is a precursor for specialized pro-resolving mediators (SPMs) like E-series resolvins, which are essential for actively terminating the inflammatory response.

Vascular reactivity and inflammation

A high AA:EPA ratio is a recognized biomarker for endothelial dysfunction and arterial stiffness.

• Vascular tone: AA-derived Thromboxane A2 (TXA2) is a potent vasoconstrictor and promoter of platelet aggregation. EPA-derived TXA3 is much weaker, and EPA-derived PGI3 promotes vasodilation. Clinical studies, including the REDUCE-IT trial (n=8,179), demonstrate that lowering this ratio improves flow-mediated dilation (FMD) and vascular tone.
• Inflammatory markers: Higher ratios correlate strongly with elevated C-reactive protein (CRP) and Interleukin-6 (IL-6). For individuals over 70, this shift is particularly significant as it may exacerbate "inflammaging"—the chronic, low-grade inflammation associated with biological aging.

Bottom line

A high AA:EPA ratio shifts eicosanoid production toward pro-inflammatory and vasoconstrictive mediators, directly increasing vascular reactivity and systemic inflammation. Correcting this ratio through EPA intake is a scientifically supported strategy to improve endothelial function and reduce inflammatory biomarkers.